These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 9667245)

  • 21. Risk factors for tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with the cyclin-dependent kinase inhibitor, flavopiridol.
    Blum KA; Ruppert AS; Woyach JA; Jones JA; Andritsos L; Flynn JM; Rovin B; Villalona-Calero M; Ji J; Phelps M; Johnson AJ; Grever MR; Byrd JC
    Leukemia; 2011 Sep; 25(9):1444-51. PubMed ID: 21606960
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Therapy-related myeloid leukemias are observed in patients with chronic lymphocytic leukemia after treatment with fludarabine and chlorambucil: results of an intergroup study, cancer and leukemia group B 9011.
    Morrison VA; Rai KR; Peterson BL; Kolitz JE; Elias L; Appelbaum FR; Hines JD; Shepherd L; Larson RA; Schiffer CA
    J Clin Oncol; 2002 Sep; 20(18):3878-84. PubMed ID: 12228208
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A phase II study of cladribine treatment for fludarabine refractory B cell chronic lymphocytic leukemia: results from CALGB Study 9211.
    Byrd JC; Peterson B; Piro L; Saven A; Vardiman JW; Larson RA; Schiffer C
    Leukemia; 2003 Feb; 17(2):323-7. PubMed ID: 12592330
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Tumor lysis syndrome in a chronic lymphocytic leukemia patient with pleural effusion after oral fludarabine and cyclophosphamide therapy.
    Nakazawa H; Nishina S; Mimura Y; Kawakami T; Senoo Y; Sakai K; Nakazawa K; Kitano K
    Int J Hematol; 2014 Jun; 99(6):782-5. PubMed ID: 24584911
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Alemtuzumab in previously treated chronic lymphocytic leukemia patients who also had received fludarabine.
    Rai KR; Freter CE; Mercier RJ; Cooper MR; Mitchell BS; Stadtmauer EA; Santábarbara P; Wacker B; Brettman L
    J Clin Oncol; 2002 Sep; 20(18):3891-7. PubMed ID: 12228210
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Long-term results with fludarabine monotherapy in chronic lymphocytic leukemia].
    Varga F; Lehoczky D; Demeter J
    Orv Hetil; 1999 Aug; 140(31):1731-5. PubMed ID: 10463032
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fludarabine treatment in B-cell chronic lymphocytic leukemia: response, toxicity and survival analysis in 47 cases.
    Stelitano C; Morabito F; Kropp MG; Callea V; Iuliano F; Oriana V; Levato D; Nobile F; Molica S; Brugiatelli M
    Haematologica; 1999 Apr; 84(4):317-23. PubMed ID: 10190945
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A 3-day schedule of fludarabine in previously treated chronic lymphocytic leukemia.
    Robertson LE; O'Brien S; Kantarjian H; Koller C; Beran M; Andreeff M; Lerner S; Plunkett W; Keating MJ
    Leukemia; 1995 Sep; 9(9):1444-9. PubMed ID: 7658710
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Efficacy of oral fludarabine in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma.
    Zhu Y; Qin Q; Xie Z
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Mar; 38(3):221-4. PubMed ID: 23545817
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase II trial of fludarabine in patients with previously treated chronic lymphocytic leukaemia.
    Hocepied AM; Falkson CI; Falkson G
    S Afr Med J; 1996 May; 86(5):549-50. PubMed ID: 8711555
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fludarabine and mitoxantrone for patients with chronic lymphocytic leukemia.
    Tsimberidou AM; Keating MJ; Giles FJ; Wierda WG; Ferrajoli A; Lerner S; Beran M; Andreeff M; Kantarjian HM; O'Brien S
    Cancer; 2004 Jun; 100(12):2583-91. PubMed ID: 15197800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Phase I-II study of oxaliplatin, fludarabine, cytarabine, and rituximab combination therapy in patients with Richter's syndrome or fludarabine-refractory chronic lymphocytic leukemia.
    Tsimberidou AM; Wierda WG; Plunkett W; Kurzrock R; O'Brien S; Wen S; Ferrajoli A; Ravandi-Kashani F; Garcia-Manero G; Estrov Z; Kipps TJ; Brown JR; Fiorentino A; Lerner S; Kantarjian HM; Keating MJ
    J Clin Oncol; 2008 Jan; 26(2):196-203. PubMed ID: 18182662
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Tumor Lysis, Adverse Events, and Dose Adjustments in 297 Venetoclax-Treated CLL Patients in Routine Clinical Practice.
    Roeker LE; Fox CP; Eyre TA; Brander DM; Allan JN; Schuster SJ; Nabhan C; Hill BT; Shah NN; Lansigan F; Yazdy M; Cheson BD; Lamanna N; Singavi AK; Coombs CC; Barr PM; Skarbnik AP; Shadman M; Ujjani CS; Tuncer HH; Winter AM; Rhodes J; Dorsey C; Morse H; Kabel C; Pagel JM; Williams AM; Jacobs R; Goy A; Muralikrishnan S; Pearson L; Sitlinger A; Bailey N; Schuh A; Kirkwood AA; Mato AR
    Clin Cancer Res; 2019 Jul; 25(14):4264-4270. PubMed ID: 31004001
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Results of the fludarabine and cyclophosphamide combination regimen in chronic lymphocytic leukemia.
    O'Brien SM; Kantarjian HM; Cortes J; Beran M; Koller CA; Giles FJ; Lerner S; Keating M
    J Clin Oncol; 2001 Mar; 19(5):1414-20. PubMed ID: 11230486
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Concomitant administration of chlorambucil limits dose intensity of fludarabine in previously treated patients with chronic lymphocytic leukemia.
    Weiss M; Spiess T; Berman E; Kempin S
    Leukemia; 1994 Aug; 8(8):1290-3. PubMed ID: 8057664
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Basic fibroblast growth factor (bFGF) and vascular endothelial growth factor (VEGF) are elevated in peripheral blood plasma of patients with chronic lymphocytic leukemia and decrease after intensive fludarabine-based treatment].
    Smolej L; Andrýs C; Krejsek J; Belada DZ; Zák P; Siroký O; Malý J
    Vnitr Lek; 2007 Nov; 53(11):1171-6. PubMed ID: 18277626
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Acute tumor lysis syndrome complicating fludarabine treatment of prolymphocytic leukemia.
    Cannon LM; Spilove L; Rhodes R; Garfinkel H; Pezzimenti J
    Conn Med; 1993 Oct; 57(10):651-4. PubMed ID: 8275684
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Incidence and risk of tumor lysis syndrome in patients with relapsed chronic lymphocytic leukemia (CLL) treated with venetoclax in routine clinical practice.
    Koehler AB; Leung N; Call TG; Rabe KG; Achenbach SJ; Ding W; Kenderian SS; Leis JF; Wang Y; Muchtar E; Hayman SR; Hampel PJ; Finnes HD; Schwager SM; Slager SL; Kay NE; Parikh SA
    Leuk Lymphoma; 2020 Oct; 61(10):2383-2388. PubMed ID: 32449401
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phase II study of single-agent bortezomib for the treatment of patients with fludarabine-refractory B-cell chronic lymphocytic leukemia.
    Faderl S; Rai K; Gribben J; Byrd JC; Flinn IW; O'Brien S; Sheng S; Esseltine DL; Keating MJ
    Cancer; 2006 Sep; 107(5):916-24. PubMed ID: 16832816
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fludarabine + prednisone +/- alpha-interferon followed or not by alpha-interferon maintenance therapy for previously untreated patients with chronic lymphocytic leukemia: long term results of a randomized study.
    Mauro FR; Zinzani P; Zaja F; Gentile M; Vegna ML; Stefoni V; Marin L; Fanin R; Baccarani M; Tura S; Mandelli F
    Haematologica; 2003 Dec; 88(12):1348-57. PubMed ID: 14687987
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.